Long-term Efficacy of Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade vs Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary RevascularizationREPLACE-2 Randomized Trial
Top Cited Papers
Open Access
- 11 August 2004
- journal article
- clinical trial
- Published by American Medical Association (AMA) in JAMA
- Vol. 292 (6) , 696-703
- https://doi.org/10.1001/jama.292.6.696
Abstract
Refined antithrombotic therapies have enhanced the safety and efficacy of percutaneous coronary intervention (PCI).1-3 A series of randomized trials established platelet glycoprotein IIb/IIIa (Gp IIb/IIIa) receptor inhibition, in addition to aspirin, heparin, and a thienopyridine (with stenting), as a reference strategy to reduce the incidence of ischemic complications during these procedures.2-4 Nevertheless, Gp IIb/IIIa inhibitors are not universally used in clinical interventional practice, due in part to concerns about increased bleeding, cost, and prolonged (12-18 hour) drug infusions. Interest therefore remains in the development of newer antithrombotic agents that may further improve outcomes during PCI.Keywords
This publication has 13 references indexed in Scilit:
- Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial)The American Journal of Cardiology, 2004
- Should Bivalirudin Replace Heparin During Percutaneous Coronary Interventions?Published by American Medical Association (AMA) ,2003
- Direct thrombin inhibitors in cardiac disease.Cardiovascular Toxicology, 2003
- Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: Results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET)American Heart Journal, 2002
- Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trialThe Lancet, 2001
- Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary interventionJournal of the American College of Cardiology, 2001
- Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery diseaseJournal of the American College of Cardiology, 2000
- A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery StentingNew England Journal of Medicine, 1998
- Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic ComplicationJAMA, 1997
- Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventionsAmerican Heart Journal, 1996